+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Generic Drugs - Global Strategic Business Report

  • PDF Icon

    Report

  • 711 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309456
The global market for Generic Drugs is estimated at US$430.2 Billion in 2023 and is projected to reach US$671.5 Billion by 2030, growing at a CAGR of 5.7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Small-Molecule Generics segment, which is expected to reach US$538.8 Billion by 2030 with a CAGR of 4.2%. The Biosimilars segment is also set to grow at 15.3% CAGR over the next 8 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $130.2 Billion in 2023, and China, forecasted to grow at an impressive 7.1% CAGR to reach $126.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Generic Drugs Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Generic Drugs Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Generic Drugs Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Abbott Laboratories, Apotex Inc., ASKA Pharmaceutical Co., Ltd., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 255 Featured):

  • Abbott Laboratories
  • Apotex Inc.
  • ASKA Pharmaceutical Co., Ltd.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca Plc
  • Baxter International Inc.
  • Dr. Reddy’s Laboratories Limited`
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • GSK plc
  • H. Lundbeck A/S
  • Incepta Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Novo Nordisk A/S
  • Sandoz International GmbH
  • Sanofi-Aventis U.S. LLC
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Global Economic Update
  • Demand for Generic Pain Killers Rises
  • A Prelude to Generic Drugs
  • Generic Drugs Market Set for a Rapid Growth
  • North America and Europe Dominate, Asia-Pacific to Exhibit the Fastest Growth
  • India- A Significant Market
  • Small-molecule Generic Drugs Account for a Lion's Share, Biosimilars Exhibit Fastest Growth
  • Exciting Times for Biosimilars
  • Competition
  • Generic Drugs - Global Key Competitors Percentage Market Share in 2023 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
  • Market Opportunities
  • Strategies to Sustain Success
  • The Future of Generics & Biosimilars Look Bright amid Persistent Barriers
  • Market Challenges
  • Factors Affecting Prices & Accessibility
  • Recent Market Activity
  • BRANDS
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Generic Drugs Enjoy Adrenaline Rush with Regulatory & Scientific Support
  • R&D & Innovation Push
  • Efforts to Eliminate Barriers to Generics Development
  • Regulatory & Scientific Collaboration as Key
  • FDA’s Generic Drug User Free Program
  • Policy Support to Generic Drugs: Clearing Road to Affordable Access to Quality Medicines
  • Savings in Billions
  • Taking GDUFA to Next Level
  • Pushing Competition through ANDAs
  • Patent Expiries Set to Widen the Addressable Market for Generic Drugs
  • Patent Expiries of Select Drugs in 2020
  • Patent Expiries of Select Drugs in 2021
  • Patent Expiries of Select Drugs in 2022
  • Patent Expiries of Select Drugs in 2023
  • Patent Expiry of Select Major Drugs in the US: 2020-2023
  • Robust Demand for Pharmaceutical Drugs Drives Demand for Generic Drugs
  • Cost Containment Measures Put Focus on Generics
  • Small Molecule Generics Represent the Dominant Segment
  • Specialty Generic Drugs Gain Popularity
  • Specialty Generics - The Way to Success Amid Challenges
  • Factors that can Provide Competitive Edge
  • Increasing Demand for Biosimilars, Driven by Patent Expiry of Major Biopharmaceutical Drugs
  • Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe in the Recent Past
  • Progressive Regulatory Framework Accelerates Product Approvals & Subsequently Market Revenues
  • Specific Guidelines for Biosimilars in Various Countries with Year of Publication
  • Biosimilars Regulatory Agencies in Select Regional Markets
  • Biosimilar Approvals in the US (as of 2023)
  • Biosimilar Approvals in Europe (as of 2023)
  • Rising Healthcare Costs Drive Demand for Generic Drugs
  • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
  • Aging Population to Propel the Demand for Generic Drugs
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Significant Increase in Number of Patients Suffering from Chronic Diseases Fuel Demand for Generic Medicines
  • Global Cost of Chronic Diseases (In US$ Billion) for the Years 2018 and 2030
  • Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Number of New Cancer Cases and Deaths (in Million) by Region for 2018
  • US Regulators Struggle to Keep Up with the Global Market
  • Increased Dependency on Non-US Manufacturers
  • Patient Trust and Traceability
  • Drug Supply Shortage Risks
  • Fixing a Broken System
  • Hospitals Teaming Up to Develop Own Generic Drugs to Combat Shortages and High Prices
  • Use of Artificial Intelligence and Machine Learning in Pharmaceutical Manufacturing Witnesses a Surge
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Generic Drugs Market Analysis of Annual Sales in US$ Million for Years 2018 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
  • Table 4: World 12-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2018, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Small-Molecule Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Small-Molecule Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
  • Table 7: World 12-Year Perspective for Small-Molecule Generics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
  • Table 10: World 12-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
  • Table 13: World 12-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
  • Table 16: World 12-Year Perspective for Central Nervous System (CNS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Dermatology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Dermatology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
  • Table 19: World 12-Year Perspective for Dermatology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2024 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 21: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
  • Table 22: World 12-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2024 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 24: World Historic Review for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
  • Table 25: World 12-Year Perspective for Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2024 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Other Therapeutic Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 27: World Historic Review for Other Therapeutic Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2022 and % CAGR
  • Table 28: World 12-Year Perspective for Other Therapeutic Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2018, 2024 & 2030
  • A Prelude to Generic Drugs
III. MARKET ANALYSIS
UNITED STATES
  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
CANADA
  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Canada for 2023 (E)
JAPAN
  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
CHINA
  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
EUROPE
  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
FRANCE
  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
GERMANY
  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
ITALY
UNITED KINGDOM
  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
AUSTRALIA
  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Generic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Apotex Inc.
  • ASKA Pharmaceutical Co., Ltd.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca Plc
  • Baxter International Inc.
  • Dr. Reddy’s Laboratories Limited`
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • GSK plc
  • H. Lundbeck A/S
  • Incepta Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Novo Nordisk A/S
  • Sandoz International GmbH
  • Sanofi-Aventis U.S. LLC
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information